SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI (SOAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01182376|
Recruitment Status : Completed
First Posted : August 16, 2010
Results First Posted : February 19, 2016
Last Update Posted : February 19, 2016
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: dronedarone Drug: Placebo||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||33 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI|
|Study Start Date :||November 2010|
|Primary Completion Date :||December 2012|
|Study Completion Date :||December 2012|
Placebo Comparator: Placebo
Half of the patients will be assigned placebo.
Placebo will be administered by the patient's team according to established guidelines.
Experimental: Multaq® (dronedarone)
Half of the patients will be prescribed dronedarone.
Dronedarone will be prescribed by the patient's team according to established guidelines.
Other Name: Multaq®
- LA Fibrosis [ Time Frame: baseline, 1 year ]The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01182376
|Principal Investigator:||Nassir F Marrouche, MD||University of Utah|